Product Description
Mechanisms of Action: CaCC Blocker
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Korea | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Genaera
Company Location: PLYMOUTH MEETING PA 19462
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Breast Cancer
Phase 2: Cystic Fibrosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| 2006-7041-83/hah | N/A |
Not yet recruiting |
Musculoskeletal Pain|Low Back Pain |
None |
|||
| 2004-004334-13 | P2 |
Completed |
Cystic Fibrosis |
2007-01-06 |
2022-03-12 |
Treatments |
|
| HECT005 | P4 |
Not yet recruiting |
Breast Cancer |
2030-12-01 |
2025-01-17 |
Primary Endpoints|Treatments |